New collaboration to discover protein biomarkers
- Published: Tuesday, 09 February 2016 11:48
- Written by University of Oxford
The University of Oxford and SomaLogic announced today that they have agreed to undertake a number of collaborative projects that will employ SomaLogic's proprietary SOMAmer® reagents and SOMAscan® assay technologies to discover and characterise protein biomarkers for a range of clinical diseases and conditions.
In order to maximize the collaborative nature of these projects and accelerate the translation of discoveries into clinical testing, the agreement also includes the build-out of a SOMAscan assay service laboratory at Oxford under the direction of SomaLogic personnel.
"We welcome SomaLogic to Oxford, one of Europe's largest centres for biotechnology research," said Simon Lovestone, Professor of Translational Neuroscience. "This agreement is a model for how we can bring together the best of industry, academia and the National Health Service to improve healthcare outcomes for patients in the UK and beyond. SomaLogic will benefit from access to Oxford's world-leading research to develop and refine its products, while we will benefit from access to technology that can enhance what we do."
"We are excited to closely join our proteomics technology and knowledge with the biomedical expertise of Oxford's world-class researchers," said Byron Hewett, CEO of SomaLogic. "The massive data that will be generated from this agreement should rapidly lead to new applications of our technologies to the clinical diagnosis and management for many diseases and conditions."
Compared to other current proteomic technologies, SomaLogic's platform gives researchers unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer reagents, which are at the centre of SomaLogic's proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates 1,310 different SOMAmer reagents, efficiently, accurately, and rapidly measures proteins across a wide range of concentrations in small volumes of multiple biological sample types, accelerating the discovery of biomarkers across a wide range of diseases and conditions.
Oxford is well placed to exploit the wealth of information generated by the SOMAscan technology. The agreement comes as Oxford completes work on its Big Data Institute, which will focus on the analysis of large data sets in an effort to improve detection, treatment and prevention of a range of conditions, adding to work in the existing Target Discovery Institute, which looks for potential new targets for treatments. Overall, the University's medical research ranges from initial lab work to clinical application in hospitals and health centres, with centres of excellence investigating a range of conditions from Cancer and Alzheimer's to rare tropical diseases. Much of that research can benefit from further proteomics support.
The Oxford University Innovation (OUI) Incubator has relaunched with a new deal on equity and access to finance for Oxford University startups.
The Novo Nordisk Research Centre Oxford has the potential to substantially impact future treatment of type 2 diabetes and its complications.
As the internet continues to grow rapidly, guaranteeing our security online becomes more and more critical.
Sir Martin Wood founded Oxford Instruments in 1959 as a spin-out company to manufacture superconducting magnets for research. See what they're working on today.
The overall objective of the programme, which is implemented jointly by a number of organisations, is to enhance the capacities of Georgian authorities.
In June 2014, Dr Max Roser made this ground-breaking publication available online, having worked on it since 2011.
This long-standing relationship has not only benefited the NAO, but has indirectly contributed to saving taxpayers’ money.
bildr, a mobile phone app, is a product created by the Frameworks project that helps Oxford graduate students and staff track how their career is developing.
The Structural Genomics Consortium (SCG) at the University of Oxford undertakes research to find the building blocks for the discovery of new drugs. A collaboration between universities, government bodies and industrial partners led by GlaxoSmithKline (GSK), the SGC has had remarkable success in mapping human proteins. An Open Access policy means that the results of the SGC’s research are freely available to all.
The Oxford-Man Institute, founded in 2007 as an innovative collaboration between the University of Oxford and Man Group, to become part of the Department of Engineering Science focused on machine learning
Thanks to a Knowledge Transfer Partnership (KTP) between the National Trust and the University of Oxford, visitors to Trust properties in London and the South East will have richer, more engaging experiences.
Deriving insights from huge chunks of data has come on at quite apace in recent years, with projects able to detect everything from oil prices to terrorist threats by wading through big data.
Oxford researchers team up with Dutch company Preceyes to work on robotic eye surgeons
Equations devised at the University of Oxford underpin modelling software used by market-leading glass companies, helping them to produce flawless products from a substance which is difficult to control.
Oxford and SomaLogic team up to work on new approaches to discovering and classifying protein biomarkers
WICKED aims to help UK retailers cut their energy consumption and save money as many retailers are not actively 'managing' how much energy they use.
Designing high performance jet engines in partnership within state-of-the-art facilities
Lighter, faster, more environmentally friendly jet engines are being created as the result of a collaboration between researchers and engineers
Developing new methods for distributed intelligent systems to share and analyse digital information was a huge academic challenge – and its solution might save lives.
Britain is heading to a low carbon future: by 2050, the UK’s greenhouse gas emissions are to be reduced by at least 80% compared to 1990 levels.